Wills Financial Group LLC Grows Stock Position in Pfizer Inc. $PFE

Wills Financial Group LLC increased its holdings in Pfizer Inc. (NYSE:PFE) by 39.7% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 152,471 shares of the biopharmaceutical company’s stock after acquiring an additional 43,318 shares during the quarter. Pfizer accounts for 1.6% of Wills Financial Group LLC’s portfolio, making the stock its 24th largest position. Wills Financial Group LLC’s holdings in Pfizer were worth $3,958,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Penn Davis Mcfarland Inc. raised its position in Pfizer by 50.9% in the fourth quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company’s stock worth $4,266,000 after acquiring an additional 57,777 shares during the period. Vanguard Group Inc. raised its stake in shares of Pfizer by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock valued at $13,479,520,000 after purchasing an additional 7,031,162 shares during the period. KBC Group NV boosted its position in shares of Pfizer by 8.3% in the fourth quarter. KBC Group NV now owns 9,193,713 shares of the biopharmaceutical company’s stock valued at $228,924,000 after acquiring an additional 706,426 shares during the period. North Dakota State Investment Board purchased a new position in shares of Pfizer during the 4th quarter valued at $5,348,000. Finally, Genesis Financial Group LLC bought a new position in Pfizer in the 4th quarter worth about $961,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA accepted Pfizer’s supplemental application for Talzenna plus Xtandi under Priority Review, a sign regulators are giving the prostate cancer expansion a faster path forward. Reuters article
• Positive Sentiment: Options activity was unusually heavy, with traders buying far more call options than normal, suggesting some investors are positioning for further upside in PFE.
• Neutral Sentiment: Articles discussing Pfizer’s roughly 7% dividend yield may help support the stock by reinforcing its income appeal, but they do not change the underlying business outlook. Motley Fool article
• Neutral Sentiment: Broader commentary on Pfizer’s oncology valuation suggests investors are still debating whether the company’s pipeline can justify a higher multiple. Kalkine Media article
• Negative Sentiment: Ongoing expanded patent litigation tied to mRNA vaccine technology remains a legal overhang and could create additional costs or uncertainty for Pfizer’s legacy COVID-19 franchise. Yahoo Finance article
• Negative Sentiment: Separately, policy risk remains a concern after reports that the Trump administration is considering steep tariffs on generic drugs, which could increase pressure across the pharmaceutical sector. Bloomberg article

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on PFE shares. Citigroup upped their price objective on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, April 29th. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Wolfe Research reissued an “underperform” rating and set a $26.00 price objective on shares of Pfizer in a research report on Thursday, May 14th. HSBC lowered Pfizer from a “buy” rating to a “hold” rating and decreased their target price for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. Finally, Guggenheim lowered their price target on shares of Pfizer from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Pfizer has an average rating of “Hold” and a consensus price target of $28.50.

Pfizer Price Performance

NYSE PFE opened at $25.02 on Friday. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a 12 month low of $23.11 and a 12 month high of $28.75. The company’s 50 day moving average is $25.13 and its two-hundred day moving average is $26.18. The stock has a market cap of $142.62 billion, a price-to-earnings ratio of 19.10 and a beta of 0.35.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. During the same quarter last year, the business posted $0.92 earnings per share. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, research analysts anticipate that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. The ex-dividend date is Friday, July 24th. Pfizer’s payout ratio is 131.30%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.